$TMNA
Tingo Inc

2023 Q2 Form 10-Q Financial Statement

#000141057823001305 Filed on May 19, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit Margin
Selling, General & Admin $11.22M $19.06M
YoY Change -69.11% -76.65%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0% -100.0%
% of Gross Profit
Operating Expenses $11.22M $19.06M
YoY Change -73.38% -78.27%
Operating Profit -$11.22M -$19.06M
YoY Change -109.2% -129.09%
Interest Expense $298.8K $293.8K
YoY Change 1159.51%
% of Operating Profit
Other Income/Expense, Net -$1.049K $159.1K
YoY Change -100.92% -14.36%
Pretax Income -$11.22M -$18.90M
YoY Change -109.19% -128.76%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.22M -$18.99M
YoY Change -115.47% -170.28%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.02
Diluted Earnings Per Share -$0.01 -$0.02
COMMON SHARES
Basic Shares Outstanding 1.228B 1.228B
Diluted Shares Outstanding 1.228B 1.228B

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.57K $32.24K
YoY Change -99.99% -99.87%
Cash & Equivalents $13.57K $32.24K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $20.07M $19.91M
YoY Change -98.67% -98.73%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.215B $1.215B
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.215B $1.215B
YoY Change 106.96% -72.98%
TOTAL ASSETS
Total Short-Term Assets $20.07M $19.91M
Total Long-Term Assets $1.215B $1.215B
Total Assets $1.235B $1.235B
YoY Change -41.21% -79.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $955.4K $926.6K
YoY Change
Accrued Expenses $4.485M $3.765M
YoY Change 108.13%
Deferred Revenue
YoY Change
Short-Term Debt $23.77M $23.75M
YoY Change 679.44%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $38.40M $37.37M
YoY Change -95.24% -95.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $38.40M $37.37M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $38.40M $37.37M
YoY Change -97.03% -97.59%
SHAREHOLDERS EQUITY
Retained Earnings $788.7M $799.9M
YoY Change 51.29% -688.37%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.197B $1.198B
YoY Change
Total Liabilities & Shareholders Equity $1.235B $1.235B
YoY Change -41.21% -79.62%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$11.22M -$18.99M
YoY Change -115.47% -170.28%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Operating Activities -$41.17K $71.25K
YoY Change -100.44% -100.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.50K -40.00K
YoY Change -99.98%
NET CHANGE
Cash From Operating Activities -41.17K 71.25K
Cash From Investing Activities
Cash From Financing Activities 22.50K -40.00K
Net Change In Cash -18.67K 31.25K
YoY Change -100.02% -100.03%
FREE CASH FLOW
Cash From Operating Activities -$41.17K $71.25K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
TINGO, INC.
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001648365
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Trading Symbol
TradingSymbol
IWBB
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
333-205835
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-0549737
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
11650 South State
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Street, Suite 240
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Draper
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10010
CY2023Q1 dei City Area Code
CityAreaCode
385
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
463-8168
CY2023Q1 dei Security12g Title
Security12gTitle
Class A Common Stock, $0.001 par value per share
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1227516211
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32239
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
985
CY2023Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
19882400
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
19637668
CY2023Q1 us-gaap Assets Current
AssetsCurrent
19914639
CY2022Q4 us-gaap Assets Current
AssetsCurrent
19638653
CY2022Q4 us-gaap Assets
Assets
1234879653
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5454543
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4286181
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
465000
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
505000
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
23749945
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
23749945
CY2023Q1 us-gaap Litigation Reserve Current
LitigationReserveCurrent
7700000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
37369488
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28541126
CY2023Q1 us-gaap Liabilities
Liabilities
37369488
CY2022Q4 us-gaap Liabilities
Liabilities
28541126
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
419181135
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
419181135
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
799892643
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
818796244
CY2023Q1 us-gaap Deferred Compensation Equity
DeferredCompensationEquity
22580143
CY2022Q4 us-gaap Deferred Compensation Equity
DeferredCompensationEquity
32931368
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1197786151
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1206338527
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1235155639
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1234879653
CY2022Q1 us-gaap Revenues
Revenues
257057519
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
2499840
CY2022Q1 us-gaap Gross Profit
GrossProfit
254557679
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
11023462
CY2022Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
19241212
CY2022Q1 us-gaap Selling Expense
SellingExpense
221187
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
299999
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
55669412
CY2022Q1 iwbb Bank Fees And Charges
BankFeesAndCharges
636047
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
106740939
CY2023Q1 iwbb General And Administrative Expenses
GeneralAndAdministrativeExpenses
7739266
CY2022Q1 iwbb General And Administrative Expenses
GeneralAndAdministrativeExpenses
838913
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
47398
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
19062727
CY2023Q1 us-gaap Long Term Investments
LongTermInvestments
1215241000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
1215241000
CY2023Q1 us-gaap Noncurrent Assets
NoncurrentAssets
1215241000
CY2022Q4 us-gaap Noncurrent Assets
NoncurrentAssets
1215241000
CY2023Q1 us-gaap Assets
Assets
1235155639
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
183395108
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19062727
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
71162571
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
452962
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
185798
CY2023Q1 us-gaap Interest Expense
InterestExpense
293836
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
159126
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
185798
CY2023Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-18903601
CY2022Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
71348369
CY2022Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
38698829
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-18903601
CY2022Q1 us-gaap Profit Loss
ProfitLoss
32649540
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-340113
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18903601
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
32309427
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1227516211
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1227516211
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1214793989
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1214793989
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
596319976
CY2022Q1 iwbb Vesting Of Deferred Stock Compensation
VestingOfDeferredStockCompensation
72039501
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
32649540
CY2022Q1 iwbb Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
ComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-340113
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
700668904
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1206338527
CY2023Q1 iwbb Vesting Of Deferred Stock Compensation
VestingOfDeferredStockCompensation
10351225
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-18993601
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1197786151
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-18903601
CY2022Q1 us-gaap Profit Loss
ProfitLoss
32649540
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
106740939
CY2022Q1 iwbb Stock Issued During Period Value Issued For Service
StockIssuedDuringPeriodValueIssuedForService
55000000
CY2023Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
10351225
CY2022Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
17039501
CY2023Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
7700000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-26605
CY2022Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-269516718
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
244732
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1168362
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-483001791
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-131929770
CY2022Q1 iwbb Increase Decrease In Value Added Tax
IncreaseDecreaseInValueAddedTax
-10208768
CY2022Q1 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
40005836
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
71254
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-104161190
CY2023Q1 iwbb Payments On Advances From Related Party
PaymentsOnAdvancesFromRelatedParty
40000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-40000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1140248
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
31254
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-103020942
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
985
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128367605
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32239
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25346663
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b>—The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts and disclosures in the financial statements. Although we believe the estimates and assumptions used in preparing these financial statements and related notes are reasonable in light of known facts and circumstances, actual results could differ from those estimates.</p>
CY2023Q1 iwbb Common Stock Number Of Classes
CommonStockNumberOfClasses
2
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-18903601
CY2022Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
32649540
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
818796244
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
416095565
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
799892643
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
448745105
CY2023Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
0
CY2023Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2022Q1 iwbb Percentage Of General Allowance On Accounts Receivable
PercentageOfGeneralAllowanceOnAccountsReceivable
0.03
CY2022Q1 iwbb Bad Debt Expense
BadDebtExpense
47000
CY2022Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2023Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.25
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.25
CY2023Q1 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2587806
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.250
CY2022Q1 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-18009875
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.250
CY2023Q1 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2587806
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.250
CY2022Q1 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-18009875
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.250
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2023Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
98269131
CY2022Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
83209591
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
98269131
CY2022Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
83209591
CY2023Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
98200000
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
16732916
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.97
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
5270703
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.96
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
11462213
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.97
CY2023Q1 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
3631949
CY2022Q4 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
3713179
CY2023Q1 us-gaap Due From Affiliate Current
DueFromAffiliateCurrent
21489
CY2022Q4 us-gaap Due From Affiliate Current
DueFromAffiliateCurrent
58489
CY2023Q1 us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.05
CY2022 us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.05
CY2023Q1 us-gaap Notes Receivable Related Parties Current
NotesReceivableRelatedPartiesCurrent
16228962
CY2022Q4 us-gaap Notes Receivable Related Parties Current
NotesReceivableRelatedPartiesCurrent
15866000
CY2023Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
19882400
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
19637668
CY2023Q1 us-gaap Debt Instrument Periodic Payment Interest
DebtInstrumentPeriodicPaymentInterest
362962
CY2023Q1 iwbb Cash And Cash Equivalents
CashAndCashEquivalents
32000
CY2022Q4 iwbb Cash And Cash Equivalents
CashAndCashEquivalents
1000
CY2023Q1 us-gaap Accounts Payable Interest Bearing Current
AccountsPayableInterestBearingCurrent
926577
CY2022Q4 us-gaap Accounts Payable Interest Bearing Current
AccountsPayableInterestBearingCurrent
1003787
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3764750
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2948013
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
763216
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
334381
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5454543
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4286181
CY2023Q1 iwbb Expenses Paid By Related Party On Behalf Of Company
ExpensesPaidByRelatedPartyOnBehalfOfCompany
465000
CY2022Q4 iwbb Expenses Paid By Related Party On Behalf Of Company
ExpensesPaidByRelatedPartyOnBehalfOfCompany
505000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001410578-23-001305-index-headers.html Edgar Link pending
0001410578-23-001305-index.html Edgar Link pending
0001410578-23-001305.txt Edgar Link pending
0001410578-23-001305-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmna-20230331.xsd Edgar Link pending
tmna-20230331x10q.htm Edgar Link pending
tmna-20230331x10q001.jpg Edgar Link pending
tmna-20230331x10q_htm.xml Edgar Link completed
tmna-20230331xex31d1.htm Edgar Link pending
tmna-20230331xex31d2.htm Edgar Link pending
tmna-20230331xex32d1.htm Edgar Link pending
tmna-20230331xex32d2.htm Edgar Link pending
tmna-20230331_lab.xml Edgar Link unprocessable
tmna-20230331_cal.xml Edgar Link unprocessable
tmna-20230331_def.xml Edgar Link unprocessable
tmna-20230331_pre.xml Edgar Link unprocessable